US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

F/m Emerald Life Sciences Innovation ETF

48.06

+0.57331.21%

Post-market: 48.060.00000.00%17:19 EDT

Volume:5K

Turnover:217.17K

Market Cap:132.51M

PE:- -

High:48.19

Open:48.00

Low:47.87

Close:47.49

52wk High:48.78

52wk Low:27.34

Shares:2.76M

Float Shares:2.76M

Volume Ratio:1.29

T/O Rate:0.16%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa

Is GH Research’s Rising Loss Per Share Reframing the GHRS Cash Burn Narrative?

Simply Wall St.

Analysts Are Bullish on These Healthcare Stocks: Spyre Therapeutics (SYRE), Revolution Medicines (RVMD)

RBC Capital Remains a Buy on GH Research (GHRS)

Analysts Have Conflicting Sentiments on These Healthcare Companies: InMode (INMD), GH Research (GHRS) and Scholar Rock Holding (SRRK)

Spyre Therapeutics Announces Grants of Inducement Awards

Oxford Biomedica trims 2026 outlook but leans on record client wins and growing pipeline

Ardelyx Says Q2 Product Revenue at Record High but Ibsrela Revenue Below Expectations

iRhythm Q2 Revenue Beats Estimates on Sustained Volume Demand, Lifts FY Guidance

Pulse Biosciences Q2 Net Loss Widens, Cash Position Strengthens

Travere Therapeutics, Inc. : Wedbush Raises Target Price to $75 from $61

THOMSON REUTERS

Regulatory Uncertainty Threatens Travere Therapeutics’ Cross-Border Deals and Partnerships

Circio’s circVec gene therapy platform secures oral slot at top European ESGCT conference

Spyre Therapeutics CEO Turtle Cameron Sells Common Shares Worth $1.42 Million

LivaNova PLC Lifts Guidance on Record Q2 Results

Takeda Wins First-in-Class U.S. Approval for Orexin Therapy in Narcolepsy Type 1

Travere Therapeutics to Present at Canaccord Genuity Growth Conference

Guardant Health Director Ian T. Clark Disposes of Common Shares Worth $2.25 Million

Akebia Q2 Revenue Falls on Lower Auryxia Sales

Sarepta Q2 Results Beat Expectations Despite Lower Sales Stemming from Elevidys Relabel, Unmet Roche Milestone

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/LFSC/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LFSC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","market":"US","secType":"STK","nameCN":"F/m Emerald Life Sciences Innovation ETF","latestPrice":48.0628,"timestamp":1787688000000,"preClose":47.4895,"halted":0,"volume":4525,"hourTrading":{"tag":"盘后","latestPrice":48.0628,"preClose":48.0628,"latestTime":"17:19 EDT","volume":118,"amount":5577.491368,"timestamp":1787692741601,"change":0,"changeRate":0,"amplitude":0.002022},"delay":0,"changeRate":0.012072142263026633,"floatShares":2757035,"shares":2757035,"eps":0,"marketStatus":"Post-Mkt","change":0.5733,"latestTime":"08-25 19:13:07 EDT","open":48,"high":48.19,"low":47.87,"amount":217171.35675,"amplitude":0.006738,"askPrice":72.16,"askSize":200,"bidPrice":47.48,"bidSize":1,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787702400000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":47.4895,"sharesOutstanding":2657035,"nav":47.8,"aum":131786273,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":48.0628,"preClose":48.0628,"latestTime":"17:19 EDT","volume":118,"amount":5577.491368,"timestamp":1787692741601,"change":0,"changeRate":0,"amplitude":0.002022},"volumeRatio":1.286754},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","floatShares":2757035,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.286754,"shares":2757035,"dividePrice":0,"high":48.19,"amplitude":0.006738,"preClose":47.4895,"low":47.87,"week52Low":27.3402,"pbRate":"--","week52High":48.78,"institutionHeld":0,"latestPrice":48.0628,"committee":-0.99005,"eps":0,"divideRate":0,"volume":4525,"delay":0,"ttmEps":0,"open":48,"prevYearClose":36.6147,"prevWeekClose":47.7953,"prevMonthClose":45.55,"prevQuarterClose":45.2033,"fiveDayClose":47.489,"twentyDayClose":45.3952,"sixtyDayClose":39.3901},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LFSC\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LFSC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LFSC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LFSC\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658993661","title":"Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa","url":"https://stock-news.laohu8.com/highlight/detail?id=2658993661","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658993661?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:00","pubTimestamp":1786363200,"startTime":"0","endTime":"0","summary":"SPY772 program aims to deliver best-in-indication efficacy and convenience in Hidradenitis Suppurativa through dual inhibition of TL1A and IL-17A/F in a long-acting coformulation Phase 2 SKYLIGHT tria","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/10/3341779/0/en/spyre-therapeutics-announces-launch-of-spy772-program-and-initiation-of-phase-2-skylight-trial-in-hidradenitis-suppurativa.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4539","BK4139","LENZ","LFSC","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658660616","title":"Is GH Research’s Rising Loss Per Share Reframing the GHRS Cash Burn Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2658660616","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658660616?lang=en_us&edition=fundamental","pubTime":"2026-08-10 07:38","pubTimestamp":1786318701,"startTime":"0","endTime":"0","summary":"GH Research PLC recently reported second-quarter 2026 results showing a net loss of US$15.15 million, up from US$9.29 million a year earlier, with basic and diluted loss per share from continuing operations rising to US$0.23 from US$0.15.\nFor the first half of 2026, the company’s net loss expanded to US$34.11 million versus US$20.10 million in the prior-year period, highlighting a meaningful increase in cash burn and pressure on its financial profile.\nWe’ll now examine how this widening net...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ghrs/gh-research/news/is-gh-researchs-rising-loss-per-share-reframing-the-ghrs-cas","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ghrs/gh-research/news/is-gh-researchs-rising-loss-per-share-reframing-the-ghrs-cas","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["GH","LU0109394709.USD","BK4007","EKG","FFOX","BK4535","BK4551","PTH","LU0889565916.HKD","GNMX","LFSC","GDOC","GNOM","HELX","BK4539","PSIL","LU0320765992.SGD","BK4196","BK4585","GHRS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657567890","title":"Analysts Are Bullish on These Healthcare Stocks: Spyre Therapeutics (SYRE), Revolution Medicines (RVMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657567890","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657567890?lang=en_us&edition=fundamental","pubTime":"2026-08-08 22:40","pubTimestamp":1786200025,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Spyre Therapeutics (SYRE) and Revolution Medicines (...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-spyre-therapeutics-syre-revolution-medicines-rvmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-spyre-therapeutics-syre-revolution-medicines-rvmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CANC","PTH","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU0889565916.HKD","IE0002141913.USD","IE00B4R5TH58.HKD","BBH","RVMD","LU0109394709.USD","IE00B2B36J28.USD","LU0320765992.SGD","BK4139","IE0009354923.USD","IE00BJT1NW94.SGD","IDNA","SYRE","LFSC","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657229326","title":"RBC Capital Remains a Buy on GH Research (GHRS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657229326","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657229326?lang=en_us&edition=fundamental","pubTime":"2026-08-08 09:45","pubTimestamp":1786153544,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Brian Abrahams maintained a Buy rating on GH Research on August 6 and set a price target of $42.00. The company’s shares closed...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-gh-research-ghrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-gh-research-ghrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LFSC","GDOC","LU0128525929.USD","GH","EKG","LU0109394709.USD","BK4535","GSIB","LU1267930573.SGD","HELX","BK4207","BK4551","BK4539","FFOX","BK4196","LU0320765992.SGD","PSIL","GNOM","PTH","LU0310800379.SGD","LU0889565916.HKD","BK4588","GHRS","BK4585","BK4007","GNMX","LU0708994859.HKD","LU0029864427.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657260426","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: InMode (INMD), GH Research (GHRS) and Scholar Rock Holding (SRRK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657260426","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657260426?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:30","pubTimestamp":1786134613,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on InMode (INMD), GH Research (GHRS) and Scholar Rock...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-inmode-inmd-gh-research-ghrs-and-scholar-rock-holding-srrk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-inmode-inmd-gh-research-ghrs-and-scholar-rock-holding-srrk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","BK4588","BK4139","BK4581","IBRN","BK4196","LABU","GH","GNOM","PSIL","SRRK","GNMX","LU0109394709.USD","PTH","LFSC","GDOC","XLV","LU0889565916.HKD","INMD","LU0320765992.SGD","HELX","BK4535","HCSG","EKG","LU0128526141.USD","BK4585","FFOX","BK4082","XBI","BK4551","BK4137","THNR","BK4007","GHRS","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657626551","title":"Spyre Therapeutics Announces Grants of Inducement Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2657626551","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657626551?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:05","pubTimestamp":1786133100,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Aug.  07, 2026  (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation t","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/07/3341387/0/en/spyre-therapeutics-announces-grants-of-inducement-awards.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","LFSC","BK4539","BK4007","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657369495","title":"Oxford Biomedica trims 2026 outlook but leans on record client wins and growing pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2657369495","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657369495?lang=en_us&edition=fundamental","pubTime":"2026-08-07 14:11","pubTimestamp":1786083103,"startTime":"0","endTime":"0","summary":"An update from Oxford BioMedica ( ($GB:OXB) ) is now available. Oxford Biomedica, a specialist cell and gene therapy CDMO, reported around 9% reven...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oxford-biomedica-trims-2026-outlook-but-leans-on-record-client-wins-and-growing-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oxford-biomedica-trims-2026-outlook-but-leans-on-record-client-wins-and-growing-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FBT","HELX","BK4585","OXM","GNOM","BK4202","WDNA","SYNB","CNCR","JDOC","BK4588","LFSC","IDNA","IBB","TBXU","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657663618","title":"Ardelyx Says Q2 Product Revenue at Record High but Ibsrela Revenue Below Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2657663618","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657663618?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:49","pubTimestamp":1786049392,"startTime":"0","endTime":"0","summary":"Ardelyx says Q2 product revenue at record high but IBSRELA revenue below expectationsOverviewU.S. biopharma firm's Q2 product revenue rose 31% yr/yr to record $118.1 mlnIBSRELA Q2 revenue grew 33% but","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431I0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARDX","LFSC","BK4007","MIRM","BK4139","TVTX","ZVRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657756668","title":"iRhythm Q2 Revenue Beats Estimates on Sustained Volume Demand, Lifts FY Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2657756668","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657756668?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:38","pubTimestamp":1786048730,"startTime":"0","endTime":"0","summary":"iRhythm Q2 revenue beats estimates on sustained volume demand, lifts FY guidanceOverviewDigital health care firm's Q2 revenue rose 20% yr/yr, beating analyst expectationsAdjusted net income turned pos","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431G3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0511384066.AUD","IRTC","LU0433182093.SGD","LU0648000940.SGD","IE00BFXG1179.USD","LU1489326972.SGD","LU0162691827.USD","LU0985489474.SGD","LU2065171311.SGD","LU1201861165.SGD","LU1894683348.USD","LU2065169927.USD","LU0266013472.USD","LU0289739343.SGD","BDX","LIVN","LU1854103824.USD","LU2065170008.USD","LU0985320562.USD","BK4504","LU0289961442.SGD","BK4082","LU0006061336.USD","LU2065171402.SGD","LFSC","LU1854104046.USD","BK4585","LU0130103400.USD","LU1150488218.USD","LU1059921491.USD","BK4563","IHI","LU0878866978.SGD","LU1894683264.USD","LU1150488135.SGD","LU1571399168.USD","LU0072461881.USD","LU0477156797.USD","LU0068578508.USD","LU0130518102.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657650423","title":"Pulse Biosciences Q2 Net Loss Widens, Cash Position Strengthens","url":"https://stock-news.laohu8.com/highlight/detail?id=2657650423","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657650423?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:21","pubTimestamp":1786047690,"startTime":"0","endTime":"0","summary":"Pulse Biosciences Q2 net loss widens, cash position strengthensOverviewBioelectric medicine company's Q2 2026 revenue grew sequentially during controlled commercial launchGAAP net loss for Q2 widened ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431GQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","LU2065170008.USD","LU2065171402.SGD","LFSC","BK4082","LU2065171311.SGD","MYO","PRCT","LU2065169927.USD","LIVN","PLSE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657363939","title":"Travere Therapeutics, Inc. : Wedbush Raises Target Price to $75 from $61","url":"https://stock-news.laohu8.com/highlight/detail?id=2657363939","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657363939?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:10","pubTimestamp":1786018250,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nFWN4431LV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LFSC","BK4139","TVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657502347","title":"Regulatory Uncertainty Threatens Travere Therapeutics’ Cross-Border Deals and Partnerships","url":"https://stock-news.laohu8.com/highlight/detail?id=2657502347","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657502347?lang=en_us&edition=fundamental","pubTime":"2026-08-06 14:01","pubTimestamp":1785996100,"startTime":"0","endTime":"0","summary":"Travere Therapeutics, Inc. (TVTX) has disclosed a new risk, in the Corporate Activity and Growth category. Travere Therapeutics, Inc. faces growing...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/regulatory-uncertainty-threatens-travere-therapeutics-cross-border-deals-and-partnerships?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/regulatory-uncertainty-threatens-travere-therapeutics-cross-border-deals-and-partnerships?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","FFTY","BK4139","LENZ","LFSC","TVTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657023575","title":"Circio’s circVec gene therapy platform secures oral slot at top European ESGCT conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2657023575","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657023575?lang=en_us&edition=fundamental","pubTime":"2026-08-06 13:45","pubTimestamp":1785995139,"startTime":"0","endTime":"0","summary":"Targovax ASA ( ($GB:0RIS) ) has shared an announcement. Circio Holding ASA, a biotechnology company specializing in circular RNA expression systems...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/circios-circvec-gene-therapy-platform-secures-oral-slot-at-top-european-esgct-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/circios-circvec-gene-therapy-platform-secures-oral-slot-at-top-european-esgct-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RDMX","LFSC","DARP","CNCR","FBT","RSPH","FHLC","IBBQ","BK4505","RNA","TBXU","AGNG","SYNB","BK4585","EPV","BK4139","FWD","IEIH","BBP","IE0009354923.USD","BK4588","IBB","JDOC","GNOM","XT","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657508141","title":"Spyre Therapeutics CEO Turtle Cameron Sells Common Shares Worth $1.42 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657508141","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657508141?lang=en_us&edition=fundamental","pubTime":"2026-08-06 09:32","pubTimestamp":1785979921,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics CEO Turtle Cameron sells common shares worth $1.42 millionSpyre Therapeutics CEO Turtle Cameron sold 15,000 common shares on Aug. 3 at weighted-average prices of $93.97 to $97.46.Ca","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDLnGFtZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Spyre Therapeutics CEO Turtle Cameron Sells Common Shares Worth $1.42 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657570531","title":"LivaNova PLC Lifts Guidance on Record Q2 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2657570531","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657570531?lang=en_us&edition=fundamental","pubTime":"2026-08-06 08:26","pubTimestamp":1785975964,"startTime":"0","endTime":"0","summary":"LivaNova PLC (($LIVN)) has held its Q2 earnings call. Read on for the main highlights of the call. LivaNova PLC’s latest earnings call painted an u...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/livanova-plc-lifts-guidance-on-record-q2-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/livanova-plc-lifts-guidance-on-record-q2-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VOTE","LU2065171311.SGD","FEBU","BK4082","JOYT","LU2065170008.USD","LFSC","LU2065171402.SGD","GXDW","LU2065169927.USD","PMDE","RGLO","VGFPF","DECU","LIVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657572786","title":"Takeda Wins First-in-Class U.S. Approval for Orexin Therapy in Narcolepsy Type 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2657572786","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657572786?lang=en_us&edition=fundamental","pubTime":"2026-08-06 07:25","pubTimestamp":1785972320,"startTime":"0","endTime":"0","summary":"The latest update is out from Takeda Pharmaceutical Co ( ($JP:4502) ). Takeda has secured U.S. FDA approval for ORZEYFUL, an oral orexin receptor 2...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/takeda-wins-first-in-class-u-s-approval-for-orexin-therapy-in-narcolepsy-type-1?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/takeda-wins-first-in-class-u-s-approval-for-orexin-therapy-in-narcolepsy-type-1?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LFSC","MRNY","RSPH","SYNB","IDNA","FRTY","BK4588","PSCH","MEDI","TBXU","IEIH","BBP","XLVX","IYH","IBB","TECB","BK4585","BMED","GDOC","PINK","GNMX","LABU","NVIB","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657757137","title":"Travere Therapeutics to Present at Canaccord Genuity Growth Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2657757137","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657757137?lang=en_us&edition=fundamental","pubTime":"2026-08-06 05:48","pubTimestamp":1785966534,"startTime":"0","endTime":"0","summary":"Travere Therapeutics to present at Canaccord Genuity Growth ConferenceTravere Therapeutics management will present at Canaccord Genuity’s 46th Annual Growth Conference on Aug. 11, 2026 at 3 p.m. ET.Ex","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL9MT5yQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0477156953.USD","LU1791807156.HKD","FTXO","LU0106831901.USD","BK4207","IYF","LU0162691827.USD","LU0203347892.USD","LU2456880835.USD","BK4585","LU0980610538.SGD","TFNS","LU1074936037.SGD","LU1366192091.USD","LU1201861249.SGD","BK4504","LU0170899867.USD","LU0052756011.USD","BK4139","BK4588","LU2125154935.USD","LU2236285917.USD","LU1244550221.USD","LU1668664300.SGD","LU0648001328.SGD","LU2360032135.SGD","LU0203345920.USD","LU0130517989.USD","LU2462157665.USD","LU0128525689.USD","LU2417539215.USD","LU0130102774.USD","LU1267930227.SGD","LU0310800965.SGD","LU0098860793.USD","TVTX","LU0072461881.USD","IE00BSNM7G36.USD","BK4566","LU1244550494.USD","LU1244550577.SGD","LU0314106906.USD","BK4534","LU0320765646.SGD","LU1162221912.USD","BK4559","LU2125154778.USD","LFSC","LU1506573853.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657726576","title":"Guardant Health Director Ian T. Clark Disposes of Common Shares Worth $2.25 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657726576","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657726576?lang=en_us&edition=fundamental","pubTime":"2026-08-06 05:11","pubTimestamp":1785964302,"startTime":"0","endTime":"0","summary":"Guardant Health director Ian T. Clark disposes of common shares worth $2.25 millionGuardant Health director Ian T. Clark reported option exercises on Aug. 4, 2026, acquiring 9,088 common shares at USD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL7mNXxZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health Director Ian T. Clark Disposes of Common Shares Worth $2.25 Million","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","GNMX","PTH","LU0320765992.SGD","BK4196","LFSC","BK4585","EKG","BK4551","BK4588","FFOX","LU0889565916.HKD","GH","LU0109394709.USD","HELX","GNOM","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657655575","title":"Akebia Q2 Revenue Falls on Lower Auryxia Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2657655575","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657655575?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:45","pubTimestamp":1785962756,"startTime":"0","endTime":"0","summary":"Akebia Q2 revenue falls on lower Auryxia salesOverviewU.S. kidney disease drugmaker's Q2 revenue fell yr/yr on lower Auryxia salesQ2 net loss and loss per share both beat analyst expectationsVafseo Q2","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4421F9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4559","BK4588","AKBA","BK4585","DVA","LFSC","BK4196","TVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657957897","title":"Sarepta Q2 Results Beat Expectations Despite Lower Sales Stemming from Elevidys Relabel, Unmet Roche Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2657957897","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657957897?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:22","pubTimestamp":1785961340,"startTime":"0","endTime":"0","summary":"Sarepta Q2 results beat expectations despite lower sales stemming from Elevidys relabel, unmet Roche milestoneOverviewUS rare disease drugmaker's Q2 revenue fell 34% yr/yr but beat analyst expectation","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4421ER:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","BCRX","SRPU","BK4139","SRPT","IE0002141913.USD","IE0009355771.USD","LFSC","IE00B2B36J28.USD","BK4585","IE00BJJMRZ35.SGD","TVTX","IE00BFTCPJ56.SGD","BK4547"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":198,"code":"91000000","status":"200"}]}}